Brian Rini, MD, FASCO

Brian I. Rini, MD, FASCO, is Ingram Professor of Medicine and Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and co-host of The Uromigos podcast.

Articles by Brian Rini, MD, FASCO

Brian Rini, MD, FASCORenal Cell Carcinoma | October 30, 2024
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
View More
Brian Rini, MD, FASCORenal Cell Carcinoma | October 30, 2024
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
Brian Rini, MD, FASCORenal Cell Carcinoma | October 30, 2024
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 30, 2024
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 30, 2024
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 29, 2024
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 29, 2024
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
Brian Rini, MD, FASCOProstate Cancer | October 29, 2024
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
Brian Rini, MD, FASCOProstate Cancer | October 29, 2024
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Brian Rini, MD, FASCORLT | October 25, 2024
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
Brian Rini, MD, FASCORLT | October 24, 2024
The first part of five segments from the Uromigos Live 2024 session on radioligands.
Brian Rini, MD, FASCORenal Cell Carcinoma | October 2, 2024
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 2, 2024
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
Brian Rini, MD, FASCORLT | October 3, 2024
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Brian Rini, MD, FASCOProstate Cancer | October 2, 2024
Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024.
Brian Rini, MD, FASCOUromigos Live 2024 | August 2, 2024
Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.